Unknown

Dataset Information

0

Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma.


ABSTRACT: BACKGROUND:Preliminary data showed prognostic impact of contrast-enhanced computed tomography (DCE-CT) identified Blood Volume (BV) in patients with metastatic renal cell carcinoma (mRCC). BV as an independent prognostic factor remains to be assessed. MATERIALS AND METHODS:DCE-CT identified BV was prospectively quantified in patients with mRCC receiving first line therapies, adjusted for International mRCC Database Consortium (IMDC) individual features and treatments, and associated with overall survival (OS), progression-free survival (PFS) and objective response (ORR), using Cox and logistic regression, respectively. RESULTS:105 patients with mRCC were included. Median baseline BV was 32.87?mL?×?100?g-1 (range 9.52 to 92.87?mL?×?100?g-1). BV above median was associated with IMDC favorable risk category (P?=?0.004), metastasis free interval???1?year (P?=?0.007), male gender (P?=?0.032), normal hemoglobin (P?=?0.040) and normal neutrophils (P?=?0.007), whereas low BV was associated with poor risk IMDC features (P?

SUBMITTER: Drljevic-Nielsen A 

PROVIDER: S-EPMC7350156 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma.

Drljevic-Nielsen Aska A   Rasmussen Finn F   Mains Jill R JR   Thorup Kennet K   Donskov Frede F  

Translational oncology 20200709 10


<h4>Background</h4>Preliminary data showed prognostic impact of contrast-enhanced computed tomography (DCE-CT) identified Blood Volume (BV) in patients with metastatic renal cell carcinoma (mRCC). BV as an independent prognostic factor remains to be assessed.<h4>Materials and methods</h4>DCE-CT identified BV was prospectively quantified in patients with mRCC receiving first line therapies, adjusted for International mRCC Database Consortium (IMDC) individual features and treatments, and associat  ...[more]

Similar Datasets

| S-EPMC6619810 | biostudies-literature
| S-EPMC10229329 | biostudies-literature
| S-EPMC4872677 | biostudies-literature
| S-EPMC5263074 | biostudies-literature
| S-EPMC6874336 | biostudies-literature
| S-EPMC9139570 | biostudies-literature
| S-EPMC9741598 | biostudies-literature
| S-EPMC6423873 | biostudies-literature
| S-EPMC3328591 | biostudies-literature